Dear Colleagues,

Human cells are continuously subjected to external stress which is able to dysregulate their normal growth inducing tumor onset and progression. Human cells normally express a control system which is able to avoid uncontrolled growth of “diseased” cells, but sometimes checkpoint systems fail and there occurs growth cells with an abnormal genetic makeup. The P53 network is particularly important to block uncontrolled proliferation of mutated cells.

Recently, the development and continuous upgrade of last generation sequencing platforms, together with the improvement of bioinformatics pipelines have permitted researchers to have access to increased information about the changes in genes expression. In this way, it has become a major focus on networks known to be key elements in tumor initiation as well as in new pathways, previously not linked to diseases (p53 network as well as NF-kB, MYC, Jak-STAT).

This will lead to increased information about individuals as well as subsets of organisms in order to develop a focused diagnostic pipeline as well as new methods for targeted transcriptional modulation. All these informatics will be used for applications in drug development and improve therapies.

The aim of this Special Issue is to publish original research as well as comprehensive reviews on the recent advances in the studies regarding the role of the p53 network in tumor onset as well as the development of strategies to counteract tumor progression and chemoresistance. In particular, we wish to shed light on the recent discoveries and technologies implemented to obtain information about transcriptional and genomic regulation to assist in diagnosis, drug development, and medical therapies.

Dr. Mariano Francesco Caratozzolo
Guest Editor